

Swedish Orphan Biovitrum Ltd
Suite 2, 3 Riverside, Granta Park
Great Abington
Cambridgeshire
CB21 6AD

Healthcare Professional Information regarding de-registration of XIAPEX®

Dear Healthcare Professional

This letter is to inform you that Sobi will discontinue the commercialisation of XIAPEX by the end of 2019.

XIAPEX is a product owned by Endo Ventures Limited ('Endo'). Currently, XIAPEX is commercialised in the EU and other European and Middle Eastern countries by Sobi. Endo and Sobi have agreed to terminate the cooperation agreement for Xiapex effective December 31, 2019. The decision to withdraw is not based on safety or efficacy concerns.

Endo and Sobi are committed to managing the de-registration of Xiapex from the Sobi territories in an ethical and transparent manner and Sobi will process the withdrawal of the EU Marketing Authorisation, which will be effective from 1 March, 2020.

Please be assured that the wellbeing of patients during the discontinuation process is of paramount importance to Sobi and we are committed to the safety and comfort of all patients during the process of transition to other therapies. We want to emphasize that, subject to product availability from our supplier, Sobi is committed to providing XIAPEX up until the end of 2019.

We would like to thank you for your interest in XIAPEX over the years and deeply regret any inconvenience this may cause you.

If you have any questions or concerns, please do not hesitate to contact us at your convenience.

After de-registration, all enquiries, questions or requests for Named Patient Use of Xiapex must be referred directly to Endo. Contact www.endo.com/contact

Yours Sincerely,

Carolyne Dyson
Business Unit Director
Sobi

NP-9054 Date of Preparation: October 2019

SWEDISH ORPHAN BIOVITRUM LTD

Suite 2, 3 Riverside, Granta Park,
Great Abington, Cambridgeshire, CB21 6AD
Phone +44 (0) 1223 891854 Fax +44 (0) 1223 893554 www.sobi-uk.co.uk